Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Terminated
Rhizen Pharmaceuticals SA
Phase 1
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for
Tenalisib in combination with Pembrolizumab in patients with cHL.
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Completed
Rhizen Pharmaceuticals SA
Phase 2
To assess the anti-tumor activity and safety of Tenalisib in patients with
relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),
Tenalisib has been evaluated as an investigational new drug in number of early clinical
studies in patients with relapsed/refractory hematological malignancies and demonstrated
acceptable safety and promising efficacy in these patients. Since these advanced
relapsed/refractory patients have limited therapeutic options, it is reasonable to continue
Tenalisib in responding patients post completion of their participation in previous clinical
studies.
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
Completed
Rhizen Pharmaceuticals SA
Phase 1/Phase 2
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of
Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
